ArticlePurinergic signalling2006
Modulation of purinergic signaling by NPP-type ectophosphodiesterases.
Article in Purinergic signalling, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 152 citations in OpenAlex.
- Inflammation, oxidative stress and purinergic signaling in pituitary neuroendocrine tumors (PitNETs).Purinergic signalling · 2026Review
- Free amino acids accelerate the time-dependent inactivation of rat liver nucleotide pyrophosphatase/phosphodiesterase Enpp3 elicited by EDTA.Amino acids · 2024Article
- Role of ENPP1 in cancer pathogenesis: Mechanisms and clinical implications (Review).Oncology letters · 2024Review
- Discovery of VH domains that allosterically inhibit ENPP1.Nature chemical biology · 2024Article
- Role of cAMP in Cardiomyocyte Viability: Beneficial or Detrimental?Circulation research · 2023Article
- Synthesis of new class of indole acetic acid sulfonate derivatives as ectonucleotidases inhibitors.RSC advances · 2023Article
- Dynamic recycling of extracellular ATP in human epithelial intestinal cells.PLoS computational biology · 2023Article
- Heparins are potent inhibitors of ectonucleotide pyrophosphatase/phospho-diesterase-1 (NPP1) - a promising target for the immunotherapy of cancer.Frontiers in immunology · 2023Article
- Synthesis and Biological Evaluation of Arylamide Sulphonate Derivatives as Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 and -3 Inhibitors.ACS omega · 2022Article
- Neutrophil extracellular traps: New players in cancer research.Frontiers in immunology · 2022Review
- Purinergic signaling as a new mechanism underlying physical exercise benefits: a narrative review.Purinergic signalling · 2021Review
- Design and Development of Autotaxin Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Autocrine and paracrine purinergic signaling in the most lethal types of cancer.Purinergic signalling · 2021Review
- Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy.RSC medicinal chemistry · 2021Article
- Effect of estradiol on enzymes of vascular extracellular nucleotide metabolism.Hormones (Athens, Greece) · 2021Article
- Structural and functional characterization of engineered bifunctional fusion proteins of CD39 and CD73 ectonucleotidases.American journal of physiology. Cell physiology · 2021Article
- Regulation of coenzyme A levels by degradation: the 'Ins and Outs'.Progress in lipid research · 2020Review
- Ectonucleotidases in Acute and Chronic Inflammation.Frontiers in pharmacology · 2020Review
- Article
- ENPP1-Fc prevents neointima formation in generalized arterial calcification of infancy through the generation of AMP.Experimental & molecular medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular nucleotides can elicit a wide array of cellular responses by binding to specific purinergic receptors. The level of ectonucleotides is dynamically controlled by their release from cells, synthesis by ectonucleoside diphosphokinases and ectoadenylate kinases, and hydrolysis by ectonucleotidases. One of the four structurally unrelated families of ectonucleotidases is represented by the NPP-type ectophosphodiesterases. Three of the seven members of the NPP family, namely NPP1-3, are known to hydrolyze nucleotides. The enzymatic action of NPP1-3 (in)directly results in the termination of nucleotide signaling, the salvage of nucleotides and/or the generation of new messengers like ADP, adenosine or pyrophosphate. NPP2 is unique in that it hydrolyzes both nucleotides and lysophospholipids and, thereby, generates products that could synergistically promote cell motility. We review here the enzymatic properties of NPPs and analyze current evidence that links their nucleotide-hydrolyzing capability to epithelial and neural functions, the immune response and cell motility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.